logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Lipoglycopeptide Antibacterial class drugs

    FiltersReset Filters
    4 results

    • dalvance

      (Dalbavancin)
      Allergan, Inc.
      Usage: DALVANCE® is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatrics caused by specific Gram-positive bacteria, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus, and various Streptococcus and Enterococcus species. Usage should target infections caused by susceptible strains to minimize resistance.

    • kimyrsa

      (oritavancin diphosphate)
      Melinta Therapeutics, LLC
      Usage: KIMYRSA® is indicated for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by specific Gram-positive bacteria, including methicillin-susceptible and resistant Staphylococcus aureus, various Streptococcus species, and vancomycin-susceptible Enterococcus faecalis. Use only for proven or suspected susceptible infections.

    • orbactiv

      (oritavancin)
      Melinta Therapeutics, LLC
      Usage: ORBACTIV® (oritavancin) is indicated for treating adult patients with acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-susceptible Enterococcus faecalis. It should be used to prevent drug-resistant bacteria and tailored based on culture results when available.

    • vibativ

      (telavancin hydrochloride)
      Cumberland Pharmaceuticals Inc.
      Usage: VIBATIV is indicated for adults with complicated skin and skin structure infections (cSSSI) and hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Gram-positive organisms, including methicillin-susceptible and -resistant Staphylococcus aureus. It may be used as empiric therapy in certain cases.